Spire Wealth Management Reduces Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Spire Wealth Management decreased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 76.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,417 shares of the company's stock after selling 17,807 shares during the period. Spire Wealth Management's holdings in Moderna were worth $154,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in MRNA. FMR LLC lifted its holdings in shares of Moderna by 7.4% during the 4th quarter. FMR LLC now owns 18,664,634 shares of the company's stock worth $776,075,000 after acquiring an additional 1,282,469 shares during the last quarter. Theleme Partners LLP raised its position in Moderna by 1.0% during the fourth quarter. Theleme Partners LLP now owns 7,306,861 shares of the company's stock valued at $303,819,000 after purchasing an additional 72,028 shares in the last quarter. Geode Capital Management LLC lifted its stake in Moderna by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock worth $300,219,000 after purchasing an additional 171,774 shares during the last quarter. Invesco Ltd. lifted its stake in Moderna by 24.3% during the fourth quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock worth $208,169,000 after purchasing an additional 979,858 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Moderna in the 4th quarter worth about $163,833,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Price Performance

Shares of MRNA traded up $1.59 during mid-day trading on Wednesday, hitting $30.28. 14,693,915 shares of the company's stock traded hands, compared to its average volume of 8,672,848. The business's 50-day moving average price is $26.59 and its 200-day moving average price is $31.60. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $129.39.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, beating the consensus estimate of ($2.92) by $0.40. Moderna had a negative net margin of 105.67% and a negative return on equity of 28.69%. The business had revenue of $108.00 million for the quarter, compared to analysts' expectations of $130.35 million. During the same quarter in the previous year, the business posted ($3.07) earnings per share. The firm's revenue for the quarter was down 35.3% compared to the same quarter last year. On average, equities research analysts predict that Moderna, Inc. will post -9.61 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on MRNA. Barclays decreased their price objective on Moderna from $45.00 to $40.00 and set an "equal weight" rating on the stock in a report on Friday, May 2nd. William Blair reiterated a "market perform" rating on shares of Moderna in a research report on Monday, June 2nd. UBS Group lowered their price objective on shares of Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Citigroup initiated coverage on shares of Moderna in a report on Thursday, March 13th. They set a "neutral" rating and a $40.00 target price on the stock. Finally, JPMorgan Chase & Co. decreased their target price on shares of Moderna from $33.00 to $26.00 and set an "underweight" rating on the stock in a research report on Thursday, May 22nd. Four research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $46.61.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.